Breast cancer is the most common cancer diagnosed in women after skin
cancer and is the second leading cause of cancer deaths in women after lung
cancer. Many women with breast cancer have family members with a history of
breast cancer, and scientists believe that vulnerability to breast cancer
sometimes has a genetic (inherited) component. Mutations (inherited genetic variations) of 2 genes (segments of DNA that are biological units of heredity) appear
to account for about 5% of breast cancers diagnosed annually in the United
States. The July 28, 2004, issue of JAMA includes
an article about using a computer program to help patients make decisions
about genetic testing for breast cancer.
BRCA1 and BRCA2 (BReast CAncer 1 and 2) are genes that have been discovered
to play a role in some breast cancers.
Most women have 2 normal copies of the BRCA1 and BRCA2 genes.
An estimated 250,000 women in the United States have a mutation
in one of these genes.
Women in general have about a 12% chance (1 in 8 women) of developing
breast cancer. Women with a BRCA1 or a BRCA2 mutation have up to an 87% lifetime risk of breast cancer. However,
this means that at least 13% of women with these mutations will not develop
Women with BRCA1 or BRCA2 mutations also have an increased lifetime risk of cancer of the
ovaries—up to 54% for BRCA1 and up to 27% for BRCA2.
Women who test positive for BRCA1 or BRCA2 mutations should undergo further screening and take
additional precautions, including frequent and early breast self-examinations,
clinical breast examinations (performed by a doctor), and regular mammograms.
They may consider other risk reduction options including the use of chemopreventive
agents, such as tamoxifen, surgical removal of the ovaries, or surgical removal
of the breasts.
Men with a BRCA2 mutation also have an
increased risk of breast cancer—a 6% lifetime risk compared with the
average lifetime risk of 0.1% in US men.
Genetic testing can determine whether a person has a specific genetic
mutation that can increase the risk of certain diseases or disorders. Genetic
tests can detect mutations in the BRCA1 and BRCA2 genes. Because most breast cancers are not caused
by genetic mutations, genetic testing may only be of value if you believe
you are at a high risk of having a BRCA1 or BRCA2 mutation. You are more likely to have these mutations
there are 3 or more women with breast cancer in a single generation
of your family
women develop breast cancer at a young age in your family (younger
than 50 years)
breast cancers in the family are often found in both breasts
there are cases of breast and ovarian cancer in the same family
Genetic counseling provides individuals and families with information
about the risks, benefits, and limitations of genetic testing, an assessment
of the probability of carrying a genetic mutation, and the options to consider
if a mutation is found.
American Cancer Society 800/227-2345 http://www.cancer.org
National Cancer Institute 800/4-CANCER (800/422-6237)http://www.cancer.gov
Gilda's Club 888/GILDA-4-U (888/445-3248)http://www.gildasclub.com
To find this and other JAMA Patient Pages, go to the Patient Page link
on JAMA's Web site at http://www.jama.com.
A Patient Page on cancer clinical trials was published in the June 9, 2004,
issue; and one on preventing cancer was published in the May 26, 2004, issue.
Sources: National Cancer Institute, American Cancer Society, Gilda's
Club, Susan G. Komen Breast Cancer Foundation
The JAMA Patient Page is a public service of JAMA. The information and recommendations appearing on this page are appropriate
in most instances, but they are not a substitute for medical diagnosis. For
specific information concerning your personal medical condition, JAMA suggests that you consult your physician. This page may be photocopied
noncommercially by physicians and other health care professionals to share
with patients. Any other print or online reproduction is subject to AMA approval.
To purchase bulk reprints, call 718/946-7424.
Parmet S, Lynm C, Glass RM. Genetics and Breast Cancer. JAMA. 2004;292(4):522. doi:10.1001/jama.292.4.522